BioPharmSignal logoBioPharmSignal

Biotech News

Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates

Seres Therapeutics (MCRB)Seres TherapeuticsClinical readout

Accomplished pharmaceutical executive brings extensive business development, licensing and finance experience Seres is implementing a focused corporate strategy to advance live biotherapeutic programs in inflammatory and immune diseases and support the readout of investigator-sponsored SER-155

Related news

MCRBSeres Therapeutics2026-06-25 11:00 EST

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

MCRBSeres Therapeutics2026-08-05 11:00 EST

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

View all latest news

Seres Therapeutics

Live Biotherapeutic Platform Seres Therapeutics develops live biotherapeutics that alter the gut microbiome to treat inflammatory and immune-mediated disease. The company previously led development of VOWST, the first orally administered FDA-approved microbiome therapeutic, before divesting it to Nestlé Health Science. SER-155 SER-155 is...

Recent company news

MCRBSeres Therapeutics2026-08-05 11:00 EST

Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs

MCRBSeres Therapeutics2026-07-08 11:00 EST

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

MCRBSeres Therapeutics2026-06-25 11:00 EST

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

MCRBSeres Therapeutics2026-06-05 11:00 EST

Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027

MCRBSeres Therapeutics2026-05-12 11:00 EST

Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference

Stock data

Close
4.82 USD
Market cap
70.98M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States